Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen: The value of C2 blood levels

Transplantation

Volumn 79, Issue 9, 2005, Pages 1164-1168

  Ferraresso, Mariana ^a   Ghio, Luciana ^b   Zacchello, Graziella ^c   Murer, Luisa ^c   Ginevri, Fabrizio ^d   Perfumo, Francesco ^d   Zanon, Gian Franco ^c   Fontana, Ines ^e   Amore, Alessandro ^f   Edefonti, Alberto ^b   Vigano, Sara ^b   Cardillo, Massimo ^a   Scalamogna, Mario ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b ICP   (Italy)

^c Department of Pediatrics ^*  (Italy)

^d Division of Ophthalmology   (Italy)

^e S Martino H   (Italy)

^f OIRM   (Italy)

Author keywords

Cyclosporine; Pediatric immunosuppression; Pediatric kidney transplantation; Pharmacokinetic; Prospective study

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CHILD; COMPLEMENT C2; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EMULSIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS;

EID: 20844463787     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000160762.37225.2B     Document Type: Conference Paper

References (22)

1. Seikaly M, Ho M, Emmett L, et al. The 12th annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2001; 5: 215.
2. Hoyer PF, Brodehl J, Ehrich JH, et al. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 1991; 5: 630.
3. Kahan BD, Kramer WG, Wideman CA, et al. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 1986; 18: 115.
4. Keown P, Lansberg D, Halloran P, et al. A randomized prospective multicenter pharmacoepidemiologic study of a cyclosporine microemulsion in stable graft recipients. Transplantation 1996; 62: 1744.
5. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002; 73: 3.
6. Levy G, Villamil F, Samuel D, et al, and the LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632.
7. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903.
8. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828.
9. International Neoral Renal Transplantation Study Group. Randomized international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157.
10. Dello Strologo L, Pontesilli C, Rizzoni G, et al. C2 monitoring: a reliable tool in pediatric renal transplant recipients. Transplantation 2003; 76: 444.
11. Ferraresso M, Ghio L, Tirelli S, et al. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination. Transplant Proc 2004; 36: 685.
12. Meier-Kriesche HU, Bonilla-Felix MA, Ferris ME, et al. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients. Pediatr Nephrol 1999; 13: 742.
13. Schwartz GJ, Haycock GB, Edelmann CM Jr., et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259.
14. Kelles A, Herman J, Tjandra-Maga TB, et al. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 1999; 3: 282.
15. Hoyer PF, Vaster U. Refining immunosuppressive protocois in pediatric renal transplant recipients. Transplant Proc 2001; 33: 3587.
16. Dunn SP. Neoral monitoring 2 hours post-dose and the pediatric transplant patient. Pediatr Transplant 2003; 7: 25.
17. Melter M, Rodeck B, Kardorff R, et al. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmune to Neoral. Transpl Int 1997; 10: 419.
18. Kovarik JM, Hoyer PF, Ettenger R, et al. Cyclosporine absorption profiles in pediatric kidney and liver transplant patients. Pediatr Nephrol 2003; 18: 1275.
19. Trompeter R, Fitzpatrick M, Hutchinson C, et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003 7: 282.
20. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193.
21. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study. Transplantation 1997; 631: 39.
22. Chavers BM, Gillingham KJ, Matas AJ. Complications by age in primary pediatric renal transplant recipients. Pediatr Nephrol 1997; 11: 399.